A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors

What is the purpose of this trial?

Phase Ib dose escalation in advanced solid tumors to identify dose for Phase II dose expansion in advanced or metastatic pancreatic cancer and KRAS-mutant colorectal cancer. Open-label, nonrandomized.

Novartis Pharmaceuticals

Start Date: 07/06/2017

End Date: 10/01/2018

Last Updated: 02/22/2018

Study HIC#: 1604017683